These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28484170)

  • 1. [Chronic myeloid leukemia and NK cell immunity].
    Ureshino H; Shindo T; Tanaka H; Kimura S
    Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic polymorphisms of
    Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
    Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
    Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allelic Polymorphisms of
    Ureshino H; Shindo T; Kojima H; Kusunoki Y; Miyazaki Y; Tanaka H; Saji H; Kawaguchi A; Kimura S
    Cancer Immunol Res; 2018 Jun; 6(6):745-754. PubMed ID: 29695383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
    La Nasa G; Caocci G; Littera R; Atzeni S; Vacca A; Mulas O; Langiu M; Greco M; Orrù S; Orrù N; Floris A; Carcassi C
    Exp Hematol; 2013 May; 41(5):424-31. PubMed ID: 23380384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
    Dumas PY; Bérard E; Bréal C; Dulucq S; Réa D; Nicolini F; Forcade E; Dufossée M; Pasquet JM; Turcq B; Bidet A; Milpied N; Déchanet-Merville J; Lafarge X; Etienne G; Mahon FX;
    Cancer Med; 2019 Sep; 8(11):4976-4985. PubMed ID: 31287239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
    Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tyrosine kinase inhibitor therapy discontinuation for chronic myelogenous leukemia to achieve clinical cure: current status and future perspectives].
    Kumagai T
    Rinsho Ketsueki; 2018; 59(10):2094-2103. PubMed ID: 30305514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients.
    Caocci G; Martino B; Greco M; Abruzzese E; Trawinska MM; Lai S; Ragatzu P; Galimberti S; Baratè C; Mulas O; Labate C; Littera R; Carcassi C; Gambacorti Passerini C; La Nasa G
    Exp Hematol; 2015 Dec; 43(12):1015-1018.e1. PubMed ID: 26306453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-free remission and immunity in chronic myeloid leukemia.
    Ureshino H
    Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
    Lee HR; Baek KH
    Oncol Rep; 2019 May; 41(5):2625-2635. PubMed ID: 30896812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation.
    Xu Z; Yin J; Sun Q; Hu J; Hong M; Qian S; Liu W
    Leuk Lymphoma; 2022 Nov; 63(11):2616-2626. PubMed ID: 35758278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cancer immunology in chronic myelogenous leukemia.
    Ureshino H; Shindo T; Kimura S
    Leuk Res; 2020 Jan; 88():106273. PubMed ID: 31765938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.
    Izumi K; Shindo T; Ngo HT; Nakayama-Hosoya K; Akahane K; Tamai M; Nguyen TTT; Kawana-Tachikawa A; Inukai T; Takaori-Kondo A
    Immunohorizons; 2021 Aug; 5(8):687-702. PubMed ID: 34433624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep molecular response in chronic myeloid leukemia: the new goal of therapy?
    Mahon FX; Etienne G
    Clin Cancer Res; 2014 Jan; 20(2):310-22. PubMed ID: 24166905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.
    Kreutzman A; Jaatinen T; Greco D; Vakkila E; Richter J; Ekblom M; Hjorth-Hansen H; Stenke L; Melo T; Paquette R; Seggewiss-Bernhardt R; Guerci-Bresler A; Talbot A; Cayuela JM; Mahon FX; Porkka K; Lipton J; Partanen J; Rousselot P; Mustjoki S
    Exp Hematol; 2012 Nov; 40(11):906-913.e1. PubMed ID: 22842045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
    Irani YD; Hughes A; Clarson J; Kok CH; Shanmuganathan N; White DL; Yeung DT; Ross DM; Hughes TP; Yong ASM
    Br J Haematol; 2020 Nov; 191(3):433-441. PubMed ID: 32352166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
    Hsieh YC; Kirschner K; Copland M
    Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.